article
COVID-19, broad-spectrum therapeutics and the magic blanket paradigm
Dr Praveen Prathapan explains why broad-spectrum therapeutics need to be identified to provide a safety net against pandemics, including COVID-19.
List view / Grid view
Drug Repurposing
news
X-ray screening reveals two promising SARS-CoV-2 drug candidates
Using a high-brilliance X-ray lightsource and protein crystallography, researchers have identified two drugs that inhibit the main protease of SARS-CoV-2.
news
Inexpensive drug protects against COVID-19 inflammation in pre-clinical trials
A drug called topotecan (TPT) was administered to mice up to four days after COVID-19 infection, reducing inflammation and morbidity.
article
COVID-19 in Europe – one year on from the first case
Sheraz Gul reviews where we are a year into the COVID-19 pandemic and the treatment options currently available. He also highlights the potential opportunities and challenges posed by SARS-CoV-2 vaccines.
news
Three common antiviral drugs effective against SARS-CoV-2 in vitro
A team has shown that tilorone, quinacrine and pyronaridine are effective at inhibiting the replication of SARS-CoV-2 in vitro.
article
What we know about COVID-19 and the inflammatory response
A year on from discovering COVID-19 we are starting to understand why some people suffer more severely after infection. Sadya Arnett discusses recent research into the interconnection between host inflammation and SARS-CoV-2.
news
In silico screening of existing drugs reveals three candidates against SARS-CoV-2
A novel in silico approach applied to drug screening has revealed three potential candidates that may interact with multiple proteins of SARS‐CoV‐2.
news
Behavioural screen in C. elegans reveals Parkinson’s drug candidates
Researchers have developed a workflow to study the behaviour of C. elegans in a high-throughput screen to identify Parkinson's disease drugs.
news
Screening of approved drugs reveals potential treatment for COVID-19
Vascor (bepridil) could be used to treat COVID-19, according to a new study which screened drugs to repurpose against SARS-CoV-2.
news
Machine learning identifies drugs to repurpose against COVID-19
A team has developed a machine learning approach to screen for and identify drugs that could be repurposed against COVID-19 in the elderly.
![Dr Jayakrishna Ambati looking into a microscope - macular degeneration research [Credit: UVA Health].](https://www.drugtargetreview.com/wp-content/uploads/Macular-degeneration-Jayakrishna-Ambati-720x500.jpg)
![Dr Jayakrishna Ambati looking into a microscope - macular degeneration research [Credit: UVA Health].](https://www.drugtargetreview.com/wp-content/uploads/Macular-degeneration-Jayakrishna-Ambati.jpg)
news
HIV drugs could be repurposed to prevent the onset of macular degeneration
Analysis reveals people taking nucleoside reverse transcriptase inhibitors are significantly less likely to develop dry macular degeneration, a leading cause of age-related vision loss.
news
Novel AI tool takes a DeepCE dive into potential drugs for COVID-19
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
news
Heparin inhibits SARS-CoV-2 invasion, finds study
Research suggests heparin could be repurposed for COVID-19 because it can bind to the SARS-CoV-2 Spike protein and prevent the virus from infecting cells in vitro.
news
New screening hub to identify COVID-19 drugs funded in Scotland
LifeArc and the Medical Research Council have funded a new drug screening facility that will be established to accelerate COVID-19 drug discovery.
article
A single approach to creating effective cancer and autoimmune disease therapeutics
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
